Nutriband (NTRB) Competitors

NeuroPace (NASDAQ:NPCE) and Nutriband (NASDAQ:NTRB) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, media sentiment, earnings, dividends and risk.

Does the media refer more to NPCE or NTRB?

In the previous week, NeuroPace had 4 more articles in the media than Nutriband. MarketBeat recorded 7 mentions for NeuroPace and 3 mentions for Nutriband. Nutriband's average media sentiment score of 1.12 beat NeuroPace's score of 0.85 indicating that Nutriband is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NeuroPace	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Nutriband	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has preferable valuation and earnings, NPCE or NTRB?

Nutriband has lower revenue, but higher earnings than NeuroPace. NeuroPace is trading at a lower price-to-earnings ratio than Nutriband, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NeuroPace	$79.91M	3.72	-$27.14M	-$0.84	-10.70
Nutriband	$2.14M	33.50	-$10.48M	-$0.90	-7.14

Is NPCE or NTRB more profitable?

NeuroPace has a net margin of -29.29% compared to Nutriband's net margin of -415.93%. Nutriband's return on equity of -68.25% beat NeuroPace's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NeuroPace	-29.29%	-168.61%	-25.48%
Nutriband	-415.93%	-68.25%	-60.40%

Which has more volatility & risk, NPCE or NTRB?

NeuroPace has a beta of 1.89, meaning that its stock price is 89% more volatile than the S&P 500. Comparatively, Nutriband has a beta of 1.13, meaning that its stock price is 13% more volatile than the S&P 500.

Do analysts rate NPCE or NTRB?

NeuroPace currently has a consensus price target of $16.60, indicating a potential upside of 84.65%. Nutriband has a consensus price target of $13.00, indicating a potential upside of 102.18%. Given Nutriband's stronger consensus rating and higher probable upside, analysts clearly believe Nutriband is more favorable than NeuroPace.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NeuroPace	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.83
Nutriband	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Do insiders and institutionals believe in NPCE or NTRB?

78.8% of NeuroPace shares are owned by institutional investors. Comparatively, 19.7% of Nutriband shares are owned by institutional investors. 20.5% of NeuroPace shares are owned by company insiders. Comparatively, 54.1% of Nutriband shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

NeuroPace and Nutriband tied by winning 8 of the 16 factors compared between the two stocks.